Sclerosis News and Research

RSS

Research identifies significant spike in neurological disorders during the covid-19 pandemic

In 2021, neurological diseases affected 3.40 billion individuals worldwide, corresponding to 43.1 % of the global population. In China, rapid demographic shifts and lifestyle changes have contributed to a continued rise in the burden of stroke, dementia, and Parkinson's disease-a trend expected to persist.

15 May 2026

Identifying the methodology gap that prevents treatment of infection-triggered chronic diseases

Thousands of Americans develop chronic persistent symptoms-such as fatigue, cognitive difficulties ("brain fog"), and other debilitating issues-each year following acute infections from Lyme disease, COVID-19, and other pathogens. Efforts to identify causes and produce treatments have failed. However, 16 leading researchers think they know part of the problem: study design.

14 May 2026

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced Qureight's AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar's Phase 2 EncompaSSc clinical trial.

From Society for Laboratory Automation and Screening (SLAS) 13 May 2026

Pregnancy not linked to increased myasthenia gravis flare-up risk

For female participants with myasthenia gravis, pregnancy is not associated with an increased risk of serious flare-ups of the disease, or new or worsening symptoms, according to a study published May 13, 2026, in Neurology, the medical journal of the American Academy of Neurology.

13 May 2026

CGRP inhibitors may reduce glaucoma risk among migraine patients

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published May 6, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

6 May 2026

New insights into ALS progression through glial cell behavior

All the core facilities of the Cibio Department of the University of Trento are involved in a study on ALS, co-funded by Fondazione AriSla, national organizations and various donors, to better understand the molecular mechanisms of slow-progressing cases.

5 May 2026

Global MS initiative opens applications for research data access

The International Progressive MS Alliance announces the MS Clinical and Imaging Data Resource (MS CIDR) is now accepting applications for data access.

4 May 2026

Scientists discover a potential new way to slow ALS disease progression

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes the progressive loss of motor neurons, which in most cases leads to respiratory failure within three to five years after diagnosis.

30 Apr 2026

Glucose acts as a metabolic signal for myelin development

Researchers at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have uncovered a surprising link between low brain sugar levels and the development of myelin - the protective coating that allows nerve cells to communicate rapidly and efficiently.

30 Apr 2026

Scientists redesign CAR-T cells to fight more than cancer

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic viral infections, and next-generation immune-cell platforms. It highlights promising engineering advances, including universal CAR-T cells, in vivo delivery, CAR-NK cells, and safety switches, while emphasizing unresolved challenges in durability, safety, scalability, and global access.

29 Apr 2026

Scientists seek to reverse neurodegeneration by eliminating harmful RNA pollution

Researchers at University of California San Diego School of Medicine, the Salk Institute and Sanford Burnham Prebys have received a four-year, $13 million award from the California Institute for Regenerative Medicine (CIRM) to investigate how to reverse age-related neurodegeneration by eliminating what the researchers call "RNA pollution" in aging neurons.

27 Apr 2026

Virtual neurology visits match in-person care outcomes

For people who see a neurology clinician for the first time, a new study has found that being seen virtually vs. in-person made no difference in how soon they needed more care.

22 Apr 2026

Poor sleep linked to higher dementia risk in epilepsy

For people with epilepsy, getting poor sleep was associated with a higher risk of dementia compared to people without epilepsy, according to a study published April 22, 2026, in Neurology, the medical journal of the American Academy of Neurology.

22 Apr 2026

New antibody mechanism selectively suppresses harmful immune responses

The immune system is our frontline protection against infection, continually searching for and destroying unknown pathogens.

22 Apr 2026

Short-term and cumulative exposure to air pollution tied to increased migraine activity

Air pollution is associated with increased migraine activity, according to a study published on April 15, 2026, in Neurology, the medical journal of the American Academy of Neurology.

17 Apr 2026

Concerns rise over breast cancer risk and gender-based efficacy of Ocrevus

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS) - a form of MS thought to affect around 15 % of patients.

17 Apr 2026

How the immune system may influence Alzheimer’s, Parkinson’s, and related diseases

This review argues that neurodegeneration is shaped not only by toxic protein buildup but also by immune signaling, with microglia and T cells able to either protect the brain or worsen damage depending on context. It also highlights aging, head injury, and viral infection as major forces that reshape CNS immunity and may influence disease progression and future treatment strategies.

16 Apr 2026

Clearing amyloid beta shows no significant impact on dementia severity

Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new Cochrane review has found.

16 Apr 2026

Study explains failure of cellular cleanup in neurodegenerative diseases

Inside every cell, a cleanup operation runs around the clock. Proteins are constantly damaged by wear and tear. Some can be repaired, while others must be dismantled and recycled.

15 Apr 2026

FDA clears investigational new drug application to test sCAR-T therapy for autoimmune conditions

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions.

10 Apr 2026